



## ILTOO Pharma announces the presentation of Phase IIb trial results for ALS

Paris, 21 November 2022

ILTOO Pharma SAS today announced that the results of MIROCALS, a Phase IIb trial in amyotrophic lateral sclerosis (ALS) using low-dose Interleukine-2 (LD-IL2), will be presented at the 2022 International Symposium on ALS/MND to be held on 6-9 December. This symposium is one of the largest annual medical and scientific conference dedicated to ALS and motor neurone disease (MND) research.

Results will be presented on Tuesday 6 December at 5:00 pm (CET) in the Clinical Trials session, entitled: ***Efficacy and safety of low dose IL-2 in ALS: The MIROCALS trial.***

Presenting authors are **Dr Gilbert Bensimon**, project coordinator of the MIROCALS trial, of the University Hospital of Nîmes, Paris-Sorbonne University and Assistance Publique Hôpitaux de Paris and **Prof Nigel Leigh**, principal investigator of the trial, of Brighton and Sussex Medical School, UK.

### About MIROCALS:

MIROCALS (NCT03039673) is an acronym for Modifying Immune Response Outcomes in ALS and is an EU H2020 funded trial. It is a randomized, placebo-controlled, double-blind, parallel group phase IIb study. Its main objective was to evaluate the clinical efficacy on survival, functional decline and safety of low-dose IL-2 as an add-on therapy to Riluzole over an 18-month period in order to establish that modifying immune responses through the enhancement of Tregs modifies the rate of ALS disease progression.

### About ALS:

ALS is an adult-onset motor neuron disease and is usually diagnosed between the ages of 40 and 70. It is a rare and life-threatening neurodegenerative disease. There is currently no cure for ALS and no effective treatment to stop or reverse the progression of the disease. Riluzole medication is currently the only medication given in Europe for the treatment of ALS. The disease affects about 42,000 patients in Europe and approximately 20,000 patients in the US.

ILTOO Pharma is dedicated to the development of immunotherapies with Low Dose IL-2 for the treatment of auto/neuroimmune and inflammatory disorders. The company is based in central Paris near to a thriving community of Bio Pharma research and commercialisation.

For further information, please visit our website at:

[www.iltoopharma.com](http://www.iltoopharma.com)